UTRF Licensee Attralus Secures $25M in Investment

Professor Jonathan Wall and his team at the UT Graduate School of Medicine have spent more than two decades investigating systemic amyloidosis. Their work played an integral role in helping launch the biopharmaceutical company Attralus with technology licensed from UTRF. Today, Attralus announced that it has secured $25 million in investment financing to work on… Read More